B
Bull
Bull · 25%NRIX
$12.11
Scenario price
$24.420
-0.518 (-2.12%)At close
Loading chart…
- High
- 25.355
- Open
- 24.890
- VWAP
- 24.68
- Volume
- 4.32M
- Mkt Cap
- 1.27B
- Low
- 24.265
- Amount
- 106.58M
- EV/EBITDA, TTM
- 14.45
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.
AI analysis of Nurix Therapeutics Inc (NRIX)
HoldNurix Therapeutics Inc is currently a hold. The stock is priced at $22.35, which is below the average analyst price target of $31. However, the RSI is at 25.756, indicating it is oversold, and the stock has shown a significant one-year change of +129.94%, suggesting potential for recovery. The main risk is the negative net income, which stood at -89,535,000 USD in Q2 2026, indicating ongoing financial losses.
Valuation Metrics
The current forward P/E ratio for Nurix Therapeutics Inc (NRIX) is 0.00, compared to its 5-year average forward P/E of -4.57.
Alphio AI Price Scenarios for NRIX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding NRIX
Events Timeline
News
8.510-10stocktwitsARK Invest Restructures Tech and Biotech Holdings
5.008-20NewsfilterNurix Appoints New Chief Human Resources Officer
7.508-07NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
9.008-04GlobenewswireNurix Launches Global Phase 3 Clinical Trial for Bexobrutideg
- 9.008-04Newsfilter
Nurix Launches Global Phase 3 Clinical Trial for Bexobrutideg
NRIX FAQ — answered by Alphio AI
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Nurix Therapeutics Inc is currently a hold. The stock is priced at $22.35, which is below the average analyst price target of $31. However, the RSI is at 25.756, indicating it is oversold, and the stock has shown a significant one-year change of +129.94%, suggesting potential for recovery. The main risk is the negative net income, which stood at -89,535,000 USD in Q2 2026, indicating ongoing financial losses.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.